NEW YORK (GenomeWeb News) – Investment bank Cantor Fitzgerald today initiated coverage of Cancer Genetics with a Buy rating and a $21 price target on its shares.

In a research note, analyst Sung Ji Nam said that challenges await companies developing and commercializing genomic tests, but Rutherford, NJ-based Cancer Genetics has strengths in leveraging clinical development collaborations with leading healthcare partners. Additionally, Nam said, the company has one of the most comprehensive sets of diagnostic services targeting cancer types.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.